← Leaderboards
Ezra Cohen
University Of Chicago
$7,350,375
Attributed
$14,756,166
Total exposure
10
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.8M · FY2005–23$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$14,756,166 · 10
By mechanism
R01$5,933,579 · 3
U01$5,121,550 · 1
R21$1,355,854 · 3
T32$1,195,678 · 1
P30$1,149,505 · 2
Top collaborators
- Dan S Kaufman6 shared
- Jill P. Mesirov6 shared
- Pablo Tamayo6 shared
- Eric T Ahrens5 shared
- Judith A. Varner4 shared
- J. Silvio Gutkind3 shared
- Olufunmilayo I Olopade3 shared
Most similar at University Of Chicago
Same institution · by research overlap
- Kunle O Odunsi$16,178,755
- Justin P. Kline$3,560,218
- Betty C Soliven$3,002,137
- Michael I Nishimura$19,220,002
- Ari Rosenberg$150,333
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsTumorImmunotherapyBaseResistanceSignal TransductionImmuneCellsNovel TherapeuticsSolid NeoplasmGenomicsTreatment EfficacyClinical TrialsDesignClinical ResearchT-LymphocyteImmune Checkpoint InhibitorHead And Neck CancerGeneticAnticancer ResearchSourceImmunooncologyImageInnovation
Grant awards (37)
Protocol Review and Monitoring Committee$183,050
P30 · FY2023 · CA · contact PI
Solid Tumor Therapeutics$32,104
P30 · FY2023 · CA · contact PI
Co-targeting the HER3 oncogenic signaling circuitry and PD-1 as a novel multimodal precision immunotherapy for HNSCC$489,974
R01 · FY2022 · CA
Protocol Review and Monitoring Committee$182,414
P30 · FY2022 · CA · contact PI
Solid Tumor Therapeutics$30,269
P30 · FY2022 · CA · contact PI
A Rational Systematic Approach to Find Combinations of Pharmacologic and Immune Therapies that Target Identifiable Oncogenic States$942,132
U01 · FY2021 · CA
Co-targeting the HER3 oncogenic signaling circuitry and PD-1 as a novel multimodal precision immunotherapy for HNSCC$499,263
R01 · FY2021 · CA
Therapeutic Targeting of Macrophage PI3Kgamma in HNSCC$472,763
R01 · FY2021 · CA
Clinical translation of 19F MRI to visualize cancer immunotherapeutic cells$459,865
R01 · FY2021 · CA
Protocol Review and Monitoring Committee$182,953
P30 · FY2021 · CA · contact PI
Solid Tumor Therapeutics$32,087
P30 · FY2021 · CA · contact PI
A Rational Systematic Approach to Find Combinations of Pharmacologic and Immune Therapies that Target Identifiable Oncogenic States$1,005,764
U01 · FY2020 · CA
Co-targeting the HER3 oncogenic signaling circuitry and PD-1 as a novel multimodal precision immunotherapy for HNSCC$513,131
R01 · FY2020 · CA
Clinical translation of 19F MRI to visualize cancer immunotherapeutic cells$501,116
R01 · FY2020 · CA
Therapeutic Targeting of Macrophage PI3Kgamma in HNSCC$471,791
R01 · FY2020 · CA
Protocol Review and Monitoring Committee$221,369
P30 · FY2020 · CA · contact PI
Solid Tumor Therapeutics$70,901
P30 · FY2020 · CA · contact PI
A Rational Systematic Approach to Find Combinations of Pharmacologic and Immune Therapies that Target Identifiable Oncogenic States$980,283
U01 · FY2019 · CA
Clinical translation of 19F MRI to visualize cancer immunotherapeutic cells$501,962
R01 · FY2019 · CA
Therapeutic Targeting of Macrophage PI3Kgamma in HNSCC$460,674
R01 · FY2019 · CA
Protocol Review and Monitoring Committee$182,373
P30 · FY2019 · CA · contact PI
A Rational Systematic Approach to Find Combinations of Pharmacologic and Immune Therapies that Target Identifiable Oncogenic States$166,667
U01 · FY2019 · CA
Solid Tumor Therapeutics$31,985
P30 · FY2019 · CA · contact PI
A Rational Systematic Approach to Find Combinations of Pharmacologic and Immune Therapies that Target Identifiable Oncogenic States$1,014,721
U01 · FY2018 · CA
Clinical translation of 19F MRI to visualize cancer immunotherapeutic cells$535,071
R01 · FY2018 · CA
Therapeutic Targeting of Macrophage PI3Kgamma in HNSCC$487,476
R01 · FY2018 · CA
A Rational Systematic Approach to Find Combinations of Pharmacologic and Immune Therapies that Target Identifiable Oncogenic States$1,011,983
U01 · FY2017 · CA
Clinical translation of 19F MRI to visualize cancer immunotherapeutic cells$540,493
R01 · FY2017 · CA
Basic Medical Research Training in Oncology$409,084
T32 · FY2014 · CA
Basic Medical Research Training in Oncology$391,554
T32 · FY2013 · CA
Maximizing Efficacy of EGFR Inhibitors by Defining Resistance Mechanisms$189,600
R21 · FY2013 · DE · contact PI
Basic Medical Research Training in Oncology$395,040
T32 · FY2012 · CA
Maximizing Efficacy of EGFR Inhibitors by Defining Resistance Mechanisms$237,000
R21 · FY2012 · DE · contact PI
Functional Infrared Imaging Predicts Radiation Mucositis$171,287
R21 · FY2008 · CA · contact PI
Functional Infrared Imaging Predicts Radiation Mucositis$160,901
R21 · FY2007 · CA · contact PI
Rapamycin as an Antineoplastic Agent$295,878
R21 · FY2006 · CA · contact PI
Rapamycin as an Antineoplastic Agent$301,188
R21 · FY2005 · CA